IBA Molecular, a worldwide leader in radiopharmaceuticals, has signed a definitive agreement to sell its U.S. subsidiary, Dulles, Va.-based IBA Molecular North America, to Illinois Health and Science.
Under IHS ownership, IBA Molecular North America will continue to operate as an independent company headquartered in Dulles, and "will be well positioned to take advantage of new product and footprint synergies," according to a news release.
IBA Molecular is jointly owned by SK Capital Partners and Ion Beam Applications S.A., while IHS is the parent company of Decatur (Ill.) Memorial Hospital and Zevacor Molecular, which is developing a new, high capacity radiopharmaceutical production facility near Indianapolis.
"We are proud of what has been accomplished by our North American team in the past three years, particularly in compliance, customer service, efficiency and research services," IBA Molecular CEO Renaud Dehareng said in a statement. "We are now poised for further growth focused on patient care and innovation. IHS is the ideal shareholder for this new phase. They share our values and commitment to customers, employees and patients, and have taken a strong leadership role in the nuclear medicine industry."
More articles on hospital transactions and valuation issues:
4 recent hospital transactions and partnerships
Hospital mergers and acquisition:how to plan and execute a successful transaction
Minnesota Valley Health Center to withdraw from Essentia affiliation